Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals
Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects
